查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867498

C-MET 和 HGF 抑制劑：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

C-MET & HGF Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 105 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球 c-MET 和 HGF 抑制劑市場規模估計為 34.8 億美元，預計到 2031 年將成長至 107.13 億美元，在 2025 年至 2031 年的預測期內，複合年成長率將達到 17.5%。

本報告對近期關稅調整和國際戰略反制措施對 C-MET 和 HGF 抑制劑的跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組進行了全面評估。

c-MET 和 HGF 抑制劑是一類標靶治療，旨在抑制肝細胞生長因子 (HGF) 及其受體 c-MET 訊號通路的異常活化。此通路參與形成過程，如增殖、侵襲、血管生成和轉移，特別是在肝細胞癌、肺癌、胃癌和腎癌等癌症。這些抑制劑包括小分子蛋白酪氨酸激酶抑制劑 (TKI) 和單株抗體，近年來已成為腫瘤藥物研發的重點。 FDA認證核可藥的卡馬替尼和替泊替尼等藥物因其已證實的臨床療效和安全性而加速了市場擴張。 2024 年，全球 c-MET 和 HGF 抑制劑的產量將達到約 2,400 萬單位，全球平均市場價格約為每單位 145 美元。

c-MET/HGF訊號通路在多種惡性腫瘤中的異常活化或過度表現為精準腫瘤學提供了明確的標靶。輝瑞和諾華的年度報告顯示，多種已通過核准的c-MET抑制劑已實現快速商業化，尤其是在晚期非小細胞肺癌（NSCLC）領域。隨著全球腫瘤市場的擴張和個人化治療通訊協定的日益普及，c-MET和HGF抑制劑在拓展適應症方面具有巨大潛力。 RNA定序等分子診斷技術的日益普及進一步加速了c-MET陽性患者的識別，並促進了治療的推廣。

儘管臨床結果令人鼓舞，但c-MET和HGF抑制劑仍面臨許多挑戰，例如療效差異、複雜的抗藥性機制以及不利事件管理等。一些早期候選藥物由於缺乏基於生物標記的標準化患者篩選方法，在III期臨床試驗中遭遇了令人失望的結果或挫折。在全球範圍內，監管機構對可靠的真實世界安全性和有效性數據的要求日益提高，這導致研發時間和成本不斷增加。

隨著精準標靶治療在臨床上的應用日益廣泛，C-MET抑制劑正被納入多重藥物治療方法。根據IQVIA和FDA的數據，目前全球正在進行多項臨床試驗，檢驗C-MET抑制劑與免疫查核點抑制劑合併聯合治療。由於醫療保險政策的完善和本土生物技術公司的崛起，預計未來幾年，C-MET抑制劑在中國、韓國及其他市場的滲透率將顯著提升。

本報告旨在對全球 C-MET 和 HGF 抑制劑市場按地區/國家、類型和應用進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以銷售量（千）和收入（百萬美元）為單位，對C-MET和HGF抑制劑的市場規模、估算和預測進行了呈現，基準年為2024年，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定C-MET和HGF抑制劑的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Takeda Pharmaceutical

按類型分類的細分市場

  • Cabozantinib
  • Crizotinib
  • 替泊替尼
  • 其他

應用領域

  • 醫院
  • 藥局

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for C-MET & HGF Inhibitors was estimated to be worth US$ 3480 million in 2024 and is forecast to a readjusted size of US$ 10713 million by 2031 with a CAGR of 17.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on C-MET & HGF Inhibitors cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

C-MET & HGF inhibitors are a class of targeted therapies designed to inhibit the aberrant activation of the hepatocyte growth factor (HGF) and its receptor c-MET signaling pathway. This axis is implicated in tumorigenesis processes such as proliferation, invasion, angiogenesis, and metastasis, especially in cancers such as hepatocellular carcinoma, lung cancer, gastric cancer, and renal cancer. The inhibitors include small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. In recent years, they have become a key focus in oncology drug development. Drugs such as Capmatinib and Tepotinib, approved by the FDA, are accelerating market expansion with demonstrated clinical efficacy and safety. In 2024, global C-MET & HGF Inhibitors production reached approximately 24 million unit, with an average global market price of around US$ 145/unit.

The abnormal activation or overexpression of the c-MET/HGF signaling pathway in multiple malignancies provides a clear target for precision oncology. As revealed in annual reports from Pfizer and Novartis, several approved C-MET inhibitors have achieved rapid commercialization, especially in late-stage NSCLC. With the expanding global oncology market and increasing adoption of individualized treatment protocols, C-MET & HGF inhibitors possess significant potential for indication expansion. The growing availability of molecular diagnostics, such as RNA sequencing, further accelerates the identification of C-MET-positive patients, boosting treatment penetration.

Despite promising clinical outcomes, C-MET & HGF inhibitors face challenges including inconsistent efficacy, complex resistance mechanisms, and adverse event management. Some early candidates have underperformed in Phase III trials or faced setbacks due to the lack of standardized biomarker-based patient selection. Regulatory pressures are mounting worldwide, demanding robust real-world evidence for safety and efficacy, thus increasing development timelines and costs.

There is growing clinical acceptance of precision-targeted therapies, integrating C-MET inhibitors into multi-line treatment regimens. According to IQVIA and FDA data, numerous global clinical trials are exploring combination therapies involving C-MET inhibitors and immune checkpoint inhibitors. In China, Korea, and other markets, reimbursement policy improvements and the rise of local biotech players are expected to significantly accelerate market penetration in the coming years.

This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of C-MET & HGF Inhibitors by region & country, by Type, and by Application.

The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.

Market Segmentation

By Company

  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Takeda Pharmaceutical

Segment by Type

  • Cabozantinib
  • Crizotinib
  • Tepotinib
  • Others

Segment by Application

  • Hospital
  • Drug Store

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of C-MET & HGF Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 C-MET & HGF Inhibitors Product Introduction
  • 1.2 Global C-MET & HGF Inhibitors Market Size Forecast
    • 1.2.1 Global C-MET & HGF Inhibitors Sales Value (2020-2031)
    • 1.2.2 Global C-MET & HGF Inhibitors Sales Volume (2020-2031)
    • 1.2.3 Global C-MET & HGF Inhibitors Sales Price (2020-2031)
  • 1.3 C-MET & HGF Inhibitors Market Trends & Drivers
    • 1.3.1 C-MET & HGF Inhibitors Industry Trends
    • 1.3.2 C-MET & HGF Inhibitors Market Drivers & Opportunity
    • 1.3.3 C-MET & HGF Inhibitors Market Challenges
    • 1.3.4 C-MET & HGF Inhibitors Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global C-MET & HGF Inhibitors Players Revenue Ranking (2024)
  • 2.2 Global C-MET & HGF Inhibitors Revenue by Company (2020-2025)
  • 2.3 Global C-MET & HGF Inhibitors Players Sales Volume Ranking (2024)
  • 2.4 Global C-MET & HGF Inhibitors Sales Volume by Company Players (2020-2025)
  • 2.5 Global C-MET & HGF Inhibitors Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers C-MET & HGF Inhibitors Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers C-MET & HGF Inhibitors Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of C-MET & HGF Inhibitors
  • 2.9 C-MET & HGF Inhibitors Market Competitive Analysis
    • 2.9.1 C-MET & HGF Inhibitors Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by C-MET & HGF Inhibitors Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Cabozantinib
    • 3.1.2 Crizotinib
    • 3.1.3 Tepotinib
    • 3.1.4 Others
  • 3.2 Global C-MET & HGF Inhibitors Sales Value by Type
    • 3.2.1 Global C-MET & HGF Inhibitors Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global C-MET & HGF Inhibitors Sales Value, by Type (2020-2031)
    • 3.2.3 Global C-MET & HGF Inhibitors Sales Value, by Type (%) (2020-2031)
  • 3.3 Global C-MET & HGF Inhibitors Sales Volume by Type
    • 3.3.1 Global C-MET & HGF Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Type (2020-2031)
    • 3.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global C-MET & HGF Inhibitors Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Drug Store
  • 4.2 Global C-MET & HGF Inhibitors Sales Value by Application
    • 4.2.1 Global C-MET & HGF Inhibitors Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global C-MET & HGF Inhibitors Sales Value, by Application (2020-2031)
    • 4.2.3 Global C-MET & HGF Inhibitors Sales Value, by Application (%) (2020-2031)
  • 4.3 Global C-MET & HGF Inhibitors Sales Volume by Application
    • 4.3.1 Global C-MET & HGF Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Application (2020-2031)
    • 4.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global C-MET & HGF Inhibitors Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global C-MET & HGF Inhibitors Sales Value by Region
    • 5.1.1 Global C-MET & HGF Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025)
    • 5.1.3 Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031)
    • 5.1.4 Global C-MET & HGF Inhibitors Sales Value by Region (%), (2020-2031)
  • 5.2 Global C-MET & HGF Inhibitors Sales Volume by Region
    • 5.2.1 Global C-MET & HGF Inhibitors Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025)
    • 5.2.3 Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031)
    • 5.2.4 Global C-MET & HGF Inhibitors Sales Volume by Region (%), (2020-2031)
  • 5.3 Global C-MET & HGF Inhibitors Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.4.2 North America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.5.2 Europe C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.6.2 Asia Pacific C-MET & HGF Inhibitors Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.7.2 South America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.3.2 United States C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.4.2 Europe C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.5.2 China C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.6.2 Japan C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.7.2 South Korea C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.8.2 Southeast Asia C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.9.2 India C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Exelixis
    • 7.1.1 Exelixis Company Information
    • 7.1.2 Exelixis Introduction and Business Overview
    • 7.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Exelixis C-MET & HGF Inhibitors Product Offerings
    • 7.1.5 Exelixis Recent Development
  • 7.2 Ipsen
    • 7.2.1 Ipsen Company Information
    • 7.2.2 Ipsen Introduction and Business Overview
    • 7.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Ipsen C-MET & HGF Inhibitors Product Offerings
    • 7.2.5 Ipsen Recent Development
  • 7.3 Pfizer
    • 7.3.1 Pfizer Company Information
    • 7.3.2 Pfizer Introduction and Business Overview
    • 7.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Pfizer C-MET & HGF Inhibitors Product Offerings
    • 7.3.5 Pfizer Recent Development
  • 7.4 Novartis
    • 7.4.1 Novartis Company Information
    • 7.4.2 Novartis Introduction and Business Overview
    • 7.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Novartis C-MET & HGF Inhibitors Product Offerings
    • 7.4.5 Novartis Recent Development
  • 7.5 Takeda
    • 7.5.1 Takeda Company Information
    • 7.5.2 Takeda Introduction and Business Overview
    • 7.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Takeda C-MET & HGF Inhibitors Product Offerings
    • 7.5.5 Takeda Recent Development
  • 7.6 Merck KGaA
    • 7.6.1 Merck KGaA Company Information
    • 7.6.2 Merck KGaA Introduction and Business Overview
    • 7.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Merck KGaA C-MET & HGF Inhibitors Product Offerings
    • 7.6.5 Merck KGaA Recent Development
  • 7.7 Takeda Pharmaceutical
    • 7.7.1 Takeda Pharmaceutical Company Information
    • 7.7.2 Takeda Pharmaceutical Introduction and Business Overview
    • 7.7.3 Takeda Pharmaceutical C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Takeda Pharmaceutical C-MET & HGF Inhibitors Product Offerings
    • 7.7.5 Takeda Pharmaceutical Recent Development

8 Industry Chain Analysis

  • 8.1 C-MET & HGF Inhibitors Industrial Chain
  • 8.2 C-MET & HGF Inhibitors Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 C-MET & HGF Inhibitors Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 C-MET & HGF Inhibitors Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. C-MET & HGF Inhibitors Market Trends
  • Table 2. C-MET & HGF Inhibitors Market Drivers & Opportunity
  • Table 3. C-MET & HGF Inhibitors Market Challenges
  • Table 4. C-MET & HGF Inhibitors Market Restraints
  • Table 5. Global C-MET & HGF Inhibitors Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global C-MET & HGF Inhibitors Revenue Market Share by Company (2020-2025)
  • Table 7. Global C-MET & HGF Inhibitors Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global C-MET & HGF Inhibitors Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market C-MET & HGF Inhibitors Price by Company (2020-2025) & (US$/Unit)
  • Table 10. Key Manufacturers C-MET & HGF Inhibitors Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers C-MET & HGF Inhibitors Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of C-MET & HGF Inhibitors
  • Table 13. Global C-MET & HGF Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global C-MET & HGF Inhibitors Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global C-MET & HGF Inhibitors Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global C-MET & HGF Inhibitors Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global C-MET & HGF Inhibitors Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global C-MET & HGF Inhibitors Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global C-MET & HGF Inhibitors Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global C-MET & HGF Inhibitors Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global C-MET & HGF Inhibitors Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global C-MET & HGF Inhibitors Price by Type (2020-2025) & (US$/Unit)
  • Table 27. Global C-MET & HGF Inhibitors Price by Type (2026-2031) & (US$/Unit)
  • Table 28. Global C-MET & HGF Inhibitors Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global C-MET & HGF Inhibitors Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global C-MET & HGF Inhibitors Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global C-MET & HGF Inhibitors Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global C-MET & HGF Inhibitors Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global C-MET & HGF Inhibitors Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global C-MET & HGF Inhibitors Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global C-MET & HGF Inhibitors Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global C-MET & HGF Inhibitors Price by Application (2020-2025) & (US$/Unit)
  • Table 39. Global C-MET & HGF Inhibitors Price by Application (2026-2031) & (US$/Unit)
  • Table 40. Global C-MET & HGF Inhibitors Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025) & (%)
  • Table 44. Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031) & (%)
  • Table 45. Global C-MET & HGF Inhibitors Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global C-MET & HGF Inhibitors Average Price by Region (2020-2025) & (US$/Unit)
  • Table 51. Global C-MET & HGF Inhibitors Average Price by Region (2026-2031) & (US$/Unit)
  • Table 52. Key Countries/Regions C-MET & HGF Inhibitors Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions C-MET & HGF Inhibitors Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions C-MET & HGF Inhibitors Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, (2026-2031) & (K Units)
  • Table 57. Exelixis Company Information
  • Table 58. Exelixis Introduction and Business Overview
  • Table 59. Exelixis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 60. Exelixis C-MET & HGF Inhibitors Product Offerings
  • Table 61. Exelixis Recent Development
  • Table 62. Ipsen Company Information
  • Table 63. Ipsen Introduction and Business Overview
  • Table 64. Ipsen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 65. Ipsen C-MET & HGF Inhibitors Product Offerings
  • Table 66. Ipsen Recent Development
  • Table 67. Pfizer Company Information
  • Table 68. Pfizer Introduction and Business Overview
  • Table 69. Pfizer C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 70. Pfizer C-MET & HGF Inhibitors Product Offerings
  • Table 71. Pfizer Recent Development
  • Table 72. Novartis Company Information
  • Table 73. Novartis Introduction and Business Overview
  • Table 74. Novartis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 75. Novartis C-MET & HGF Inhibitors Product Offerings
  • Table 76. Novartis Recent Development
  • Table 77. Takeda Company Information
  • Table 78. Takeda Introduction and Business Overview
  • Table 79. Takeda C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 80. Takeda C-MET & HGF Inhibitors Product Offerings
  • Table 81. Takeda Recent Development
  • Table 82. Merck KGaA Company Information
  • Table 83. Merck KGaA Introduction and Business Overview
  • Table 84. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 85. Merck KGaA C-MET & HGF Inhibitors Product Offerings
  • Table 86. Merck KGaA Recent Development
  • Table 87. Takeda Pharmaceutical Company Information
  • Table 88. Takeda Pharmaceutical Introduction and Business Overview
  • Table 89. Takeda Pharmaceutical C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 90. Takeda Pharmaceutical C-MET & HGF Inhibitors Product Offerings
  • Table 91. Takeda Pharmaceutical Recent Development
  • Table 92. Key Raw Materials Lists
  • Table 93. Raw Materials Key Suppliers Lists
  • Table 94. C-MET & HGF Inhibitors Downstream Customers
  • Table 95. C-MET & HGF Inhibitors Distributors List
  • Table 96. Research Programs/Design for This Report
  • Table 97. Key Data Information from Secondary Sources
  • Table 98. Key Data Information from Primary Sources

List of Figures

  • Figure 1. C-MET & HGF Inhibitors Product Picture
  • Figure 2. Global C-MET & HGF Inhibitors Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global C-MET & HGF Inhibitors Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global C-MET & HGF Inhibitors Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global C-MET & HGF Inhibitors Sales Price (2020-2031) & (US$/Unit)
  • Figure 6. C-MET & HGF Inhibitors Report Years Considered
  • Figure 7. Global C-MET & HGF Inhibitors Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global C-MET & HGF Inhibitors Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by C-MET & HGF Inhibitors Revenue in 2024
  • Figure 10. C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Cabozantinib Picture
  • Figure 12. Crizotinib Picture
  • Figure 13. Tepotinib Picture
  • Figure 14. Others Picture
  • Figure 15. Global C-MET & HGF Inhibitors Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global C-MET & HGF Inhibitors Sales Value Market Share by Type, 2024 & 2031
  • Figure 17. Global C-MET & HGF Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 18. Global C-MET & HGF Inhibitors Sales Volume Market Share by Type, 2024 & 2031
  • Figure 19. Global C-MET & HGF Inhibitors Price by Type (2020-2031) & (US$/Unit)
  • Figure 20. Product Picture of Hospital
  • Figure 21. Product Picture of Drug Store
  • Figure 22. Global C-MET & HGF Inhibitors Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 23. Global C-MET & HGF Inhibitors Sales Value Market Share by Application, 2024 & 2031
  • Figure 24. Global C-MET & HGF Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 25. Global C-MET & HGF Inhibitors Sales Volume Market Share by Application, 2024 & 2031
  • Figure 26. Global C-MET & HGF Inhibitors Price by Application (2020-2031) & (US$/Unit)
  • Figure 27. North America C-MET & HGF Inhibitors Sales Value (2020-2031) & (US$ Million)
  • Figure 28. North America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Europe C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Asia Pacific C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Asia Pacific C-MET & HGF Inhibitors Sales Value by Region (%), 2024 VS 2031
  • Figure 33. South America C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. South America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Middle East & Africa C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Middle East & Africa C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Key Countries/Regions C-MET & HGF Inhibitors Sales Value (%), (2020-2031)
  • Figure 38. Key Countries/Regions C-MET & HGF Inhibitors Sales Volume (%), (2020-2031)
  • Figure 39. United States C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. United States C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 41. United States C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Europe C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Europe C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Europe C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 45. China C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. China C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 47. China C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Japan C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Japan C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Japan C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 51. South Korea C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. South Korea C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 53. South Korea C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Southeast Asia C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. Southeast Asia C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 56. Southeast Asia C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 57. India C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. India C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 59. India C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 60. C-MET & HGF Inhibitors Industrial Chain
  • Figure 61. C-MET & HGF Inhibitors Manufacturing Cost Structure
  • Figure 62. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 63. Bottom-up and Top-down Approaches for This Report
  • Figure 64. Data Triangulation
  • Figure 65. Key Executives Interviewed